Presentation

0 Comments

18 December 2016

Optimising antithrombotic therapy for high-risk percutaneous coronary intervention

Makis Deliargyris

Questions To Industry III: Optimising antithrombotic therapy for high-risk percutaneous coronary intervention

Previous | Next
Download

Summary

Makis Deliargyris discusses the use of anti-thrombotic therapy for high-risk PCI.

Makis presents data from studies involving the use of heparin, GPIIb/IIIa inhibitors and bivalirudin.

Download

Summary

Makis Deliargyris discusses the use of anti-thrombotic therapy for high-risk PCI.

Makis presents data from studies involving the use of heparin, GPIIb/IIIa inhibitors and bivalirudin.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In